NEW YORK (GenomeWeb) – Interpace Diagnostics reported after the close of the market on Tuesday that its fourth quarter revenues rose nearly 32 percent year over year.
For the three-month period ended Dec. 31, 2018 Interpace's revenues rose to $5.8 million from $4.4 million in the same period the year before, matching the analysts' average estimate.
Interpace reported a Q4 net loss of $4.0 million, or $.14 per share, versus a year-ago loss of $5 million, or $.19 per share. The firm fell short of the analysts' average estimate of a loss of $0.08 loss per share.